Prediction of acute clinical response following a first episode of non affective psychosis: Results of a cohort of 375 patients from the Spanish PAFIP study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 44, Issue , 2013, Pages 162-167

  Crespo Facorro, Benedicto ^a,b   de la Foz, Victor Ortiz Garcia ^a,b   Ayesa Arriola, Rosa ^a,b   Pérez Iglesias, Rocío ^b,c   Mata, Ignacio ^a,b   Suarez Pinilla, Paula ^a   Tabares Seisdedos, Rafael ^d   Vázquez Barquero, José Luis ^a,b  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Antipsychotic agents; Prevention and control; Schizophrenia; Therapy

Indexed keywords

ARIPIPRAZOLE; CLONAZEPAM; HALOPERIDOL; LITHIUM; LORMETAZEPAM; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTRALINE; ZIPRASIDONE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; ARTICLE; CHI SQUARE TEST; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SPAIN; TREATMENT DURATION;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; SPAIN; YOUNG ADULT;

EID: 84875262461     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.02.009     Document Type: Article

References (38)

1. Amminger G.P., Resch F., Mutschlechner R., Friedrich M.H., Ernst E. Premorbid adjustment and remission of positive symptoms in first-episode psychosis. Eur Child Adolesc Psychiatry 1997, 6:212-218.
2. Andreasen N.C. Scale for the Assessment of Negative symptoms (SANS) 1983, University of Iowa, Iowa City.
3. Andreasen N.C. Scale for the Assessment of Positive Symptoms (SAPS) 1984, University of Iowa, Iowa City.
4. Bartko G., Frecska E., Horvath S., Zador G., Arato M. Predicting neuroleptic response from a combination of multilevel variables in acute schizophrenic patients. Acta Psychiatr Scand 1990, 82:408-412.
5. Cannon-Spoor H.E., Potkin S.G., Wyatt R.J. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull 1982, 8:470-484.
6. Craig T.J., Bromet E.J., Fennig S., Tanenberg-Karant M., Lavelle J., Galambos N. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series?. Am J Psychiatry 2000, 157:60-66.
7. Crespo-Facorro B., Perez-Iglesias R., Ramirez-Bonilla M., Martinez-Garcia O., Llorca J., Luis Vazquez-Barquero J. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry 2006, 67:1511-1521.
8. Crespo-Facorro B., Pelayo-Teran J.M., Perez-Iglesias R., Ramirez-Bonilla M., Martinez-Garcia O., Pardo-Garcia G., Vazquez-Barquero J.L. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J Psychiatr Res 2007, 41:659-666.
9. Crespo-Facorro B, Perez-Iglesias R, Mata I, Ortiz V, Valdizan E, Vazquez-Barquero JL. Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: Results of a 6-week, randomized, flexible-dose, open-label comparison. J Clin Psychopharmacol in press. http://dx.doi.org/10.1097/JCP.0b013e3182825c1e.
10. Cuesta M.J., Peralta V., de Leon J. Schizophrenic syndromes associated with treatment response. Prog Neuropsychopharmacol Biol Psychiatry 1994, 18:87-99.
11. Drake R.J., Haley C.J., Akhtar S., Lewis S.W. Causes and consequences of duration of untreated psychosis in schizophrenia. Br J Psychiatry 2000, 177:511-515.
12. Esterberg M.L., Trotman H.D., Holtzman C., Compton M.T., Walker E.F. The impact of a family history of psychosis on age-at-onset and positive and negative symptoms of schizophrenia: a meta-analysis. Schizophr Res 2010, 120:121-130.
13. Fanous A.H., Kendler K.S. Genetic heterogeneity, modifier genes, and quantitative phenotypes in psychiatric illness: searching for a framework. Mol Psychiatry 2005, 10:6-13.
14. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). Biometrics Research Department, New York; 2001.
15. Gaebel W. Prediction of response to acute neuroleptic treatment in schizophrenia. Int Clin Psychopharmacol 1996, 11(Suppl. 2):47-54.
16. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, 217-222. US Department of Health, Education, and Welfare Publication ADM 76338, Washington, DC.
17. Hatta K., Nakamura H., Matsuzaki I. Acute-phase treatment in general hospitals: clinical psychopharmacologic evaluation in first-episode schizophrenia patients. Gen Hosp Psychiatry 2003, 25:39-45.
18. Johnstone E.C., Macmillan J.F., Frith C.D., Benn D.K., Crow T.J. Further investigation of the predictors of outcome following first schizophrenic episodes. Br J Psychiatry 1990, 157:182-189.
19. Joober R., Rouleau G.A., Lal S., Bloom D., Lalonde P., Labelle A., Benkelfat C. Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients. Schizophr Res 2005, 77:35-41.
20. Kinon B.J., Kane J.M., Chakos M., Munne R. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacol Bull 1993, 29:365-369.
21. Larsen T.K., McGlashan T.H., Moe L.C. First-episode schizophrenia: I. Early course parameters. Schizophr Bull 1996, 22:241-256.
22. Larsen T.K., Moe L.C., Vibe-Hansen L., Johannessen J.O. Premorbid functioning versus duration of untreated psychosis in 1year outcome in first-episode psychosis. Schizophr Res 2000, 45:1-9.
23. Loebel A.D., Lieberman J.A., Alvir J.M., Mayerhoff D.I., Geisler S.H., Szymanski S.R. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992, 149:1183-1188.
24. Malaspina D., Goetz R.R., Yale S., Berman A., Friedman J.H., Tremeau F., Printz D., Amador X., Johnson J., Brown A., Gorman J.M. Relation of familial schizophrenia to negative symptoms but not to the deficit syndrome. Am J Psychiatry 2000, 157:994-1003.
25. Malla A.K., Norman R.M., Manchanda R., Ahmed M.R., Scholten D., Harricharan R., Cortese L., Takhar J. One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophr Res 2002, 54:231-242.
26. Marshall M., Lewis S., Lockwood A., Drake R., Jones P., Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Neurol Psychiatry 2005, 62:975-983.
27. McEvoy J.P., Schooler N.R., Wilson W.H. Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacol Bull 1991, 27:97-101.
28. Murray R.M., O'Callaghan E., Castle D.J., Lewis S.W. A neurodevelopmental approach to the classification of schizophrenia. Schizophr Bull 1992, 18:319-332.
29. Norman R.M., Malla A.K., Manchanda R. Early premorbid adjustment as a moderator of the impact of duration of untreated psychosis. Schizophr Res 2007, 95:111-114.
30. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol Rep 1962, 10:799-812.
31. Palao D.J., Arauxo A., Brunet M., Marquez M., Bernardo M., Ferrer J., Gonzalez-Monclus E. Positive versus negative symptoms in schizophrenia: response to haloperidol. Prog Neuropsychopharmacol Biol Psychiatry 1994, 18:155-164.
32. Pelayo-Teran J.M., Perez-Iglesias R., Ramirez-Bonilla M., Gonzalez-Blanch C., Martinez-Garcia O., Pardo-Garcia G., Rodriguez-Sanchez J.M., Roiz-Santianez R., Tordesillas-Gutierrez D., Mata I., Vazquez-Barquero J.L., Crespo-Facorro B. Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis. Early Interv Psychiatry 2008, 2:178-187.
33. Perkins D., Lieberman J., Gu H., Tohen M., McEvoy J., Green A., Zipursky R., Strakowski S., Sharma T., Kahn R., Gur R., Tollefson G. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004, 185:18-24.
34. Rabinowitz J., De Smedt G., Harvey P.D., Davidson M. Relationship between premorbid functioning and symptom severity as assessed at first episode of psychosis. Am J Psychiatry 2002, 159:2021-2026.
35. Robinson D.G., Woerner M.G., Alvir J.M., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Bilder R., Goldman R., Lieberman J.A. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999, 156:544-549.
36. Silverman J.M., Mohs R.C., Davidson M., Losonczy M.F., Keefe R.S., Breitner J.C., Sorokin J.E., Davis K.L. Familial schizophrenia and treatment response. Am J Psychiatry 1987, 144:1271-1276.
37. Ucok A., Polat A., Genc A., Cakir S., Turan N. Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. J Psychiatr Res 2004, 38:163-168.
38. Wyatt R.J. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991, 17:325-351.